Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 600 percent over the past decade.
But the drugmaker didn’t budge on its price hikes Thursday, which have drawn ire both in Congress and from families that have had to shell out increasingly large sums for the potentially life-saving treatment.
That means the insurers and employers that pay the bulk of the EpiPen cost for many patients will continue to do so, contributing to higher health insurance costs.
“That’s just going to come out in the premiums,” said Sabrina Corlette, a research professor at the Georgetown University’s Health Policy Institute. “Everybody suffers, except the Mylan investors.”
Mylan joins a growing list of drugmakers, Turing Pharmaceuticals and Valeant Pharmaceuticals International Inc. among them, that have been called out after mammoth price hikes for the drugs they sell, with little or no innovation.
Turing’s former CEO Martin Shkreli became the poster child of pharmaceutical industry greed last fall for hiking the price of a life-saving drug, Daraprim, by more than 5,000 percent.
He has applauded Mylan’s actions.
The average price of a two-dose EpiPen package climbed to about $608 earlier this year, up from around $94 nine years ago, according to the Elsevier Clinical Solutions’ Gold Standard Drug Database.
Mylan CEO Heather Bresch told CNBC on Thursday that lowering the price was not an option.
“Had we reduced the list price, I couldn’t ensure that everyone who needs an EpiPen gets one,” she said.
EpiPens are used in emergencies to treat severe allergies that can lead to anaphylactic shock. Roughly 40 million Americans have severe allergies to spider bites, bee stings and foods like nuts, eggs and shellfish.
Democratic presidential candidate Hillary Clinton and members of Congress from both parties have quickly ramped up criticism of the price Mylan charges for the medicine.
Clinton said Wednesday that pharmaceutical and biotech industries can fuel American innovation, and combat debilitating diseases. But she added that “it’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them.”
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less